预约演示
更新于：2026-03-11
GSK-3052230
更新于：2026-03-11
概要
基本信息
在研机构- |
最高研发阶段暂停临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 150418
Sequence Code 1117836251
关联
4
项与 GSK-3052230 相关的临床试验NCT01868022
Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling
NCT01604863
Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies
NCT01244438
An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations
100 项与 GSK-3052230 相关的临床结果
登录后查看更多信息
100 项与 GSK-3052230 相关的转化医学
登录后查看更多信息
100 项与 GSK-3052230 相关的专利（医药）
登录后查看更多信息
8
项与 GSK-3052230 相关的文献（医药）2020-04-01Investigational new drugs3区 · 医学
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
3区 · 医学
Article
作者: López, Pilar Garrido ; Morgensztern, Daniel ; Vasquez, James ; Mitrica, Ionel ; Orlov, Sergey ; Fennell, Dean A ; Wang, Xiaowei ; Gadgeel, Shirish ; Viteri, Santiago ; Baker-Neblett, Katherine ; Kindler, Hedy L ; Zauderer, Marjorie G ; Kostorov, Vladimir ; Levchenko, Evgeny ; DeYoung, M Phillip ; Trigo, José ; Bellovin, David I ; Yan, Li ; van Brummelen, Emilie M J ; Dómine, Manuel ; Schellens, Jan H M ; Vansteenkiste, Johan F
Background Fibroblast growth factors (FGFs) have a fundamental role in cancer. Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. Methods A multicenter, open-label, phase Ib study evaluated weekly GSK3052230 added to pemetrexed/cisplatin in patients with treatment-naive, unresectable malignant pleural mesothelioma. Doses were escalated according to a 3 + 3 design, followed by cohort expansion at the maximum tolerated dose (MTD). Endpoints included safety, overall response rate, progression-free survival, and pharmacokinetics. Results 36 patients were dosed at 10, 15, and 20 mg/kg doses of GSK3052230. Three dose-limiting toxicities were observed at 20 mg/kg and one at 15 mg/kg. The MTD was defined as 15 mg/kg and used for cohort expansion. The most common treatment-related adverse events (AEs) were nausea (56%), decreased appetite (36%), infusion reactions (36%), decreased neutrophil counts (36%), and fatigue (33%). The confirmed ORR was 39% (95% CI: 23.1-56.5) (14/36 PRs) and 47% had stable disease (17/36), giving a disease control rate of 86%. At 15 mg/kg GSK3052230 (n = 25), the ORR was 44% (95% CI: 24.4-65.1), and the median PFS was 7.4 months (95% CI: 6.7-13.4). Four patients had disease control for over 1 year, and three were still ongoing. Conclusion At 15 mg/kg weekly, GSK3052230 was well tolerated in combination with pemetrexed/cisplatin and durable responses were observed. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
2019-10-01Lung cancer (Amsterdam, Netherlands)2区 · 医学
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
2区 · 医学
Article
作者: Vasquez, James ; Baker-Neblett, Katherine ; Orlov, Sergey ; Delgado, Ignacio ; Wang, Xiaowei ; Morgensztern, Daniel ; DeYoung, M Phillip ; Shomova, Marina ; Burdaeva, Olga ; Trigo, José ; Karaseva, Nina ; Garrido, Pilar ; Lassen, Ulrik ; Dómine, Manuel ; Felip, Enriqueta ; Paik, Paul K ; Yan, Li ; Mitrica, Ionel ; Lara, Primo
OBJECTIVES:
GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule is predicted to avoid toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. Herein we report the results of a phase 1b study where GSK3052330 was administered with standard of care chemotherapy in FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC) patients.
METHODS AND METHODS:
Eligible patients with stage IV or recurrent metastatic sqNSCLC harboring FGFR1 gene amplification received escalating doses of GSK3052230 in combination with paclitaxel and carboplatin at the starting doses 200 mg/m2 and AUC of 6, respectively, in the first line setting (Arm A) or docetaxel 75 mg/m2 in second line (Arm B). The primary endpoints of the study were safety and tolerability, to identify a maximum tolerated dose (MTD), and to assess overall response rate (ORR) based on investigator assessment.
RESULTS:
Twenty-nine patients were enrolled into the study, including 20 patients on Arm A and 9 patients on Arm B. There were no dose limiting toxicities in either Arm and the MTD was not reached. The most common adverse events (AEs) were compatible with the chemotherapy backbone used in each Arm, including neutropenia, alopecia, nausea, arthralgia, asthenia, diarrhea and peripheral neuropathy. The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B.
CONCLUSION:
GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
2016-06-28Oncotarget
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
Article
作者: Tunstead, James ; Sherk, Christian ; Fricko, Maggie ; Minthorn, Elisabeth ; Barnette, Mary ; Alsaid, Hasan ; Skedzielewski, Tina ; Jucker, Beat M. ; Kumar, Rakesh ; DeYoung, M. Phillip ; Ganji, Gopinath ; Blackwell, Christina ; Hoang, Bao
Fibroblast growth factor (FGF) ligand-dependent signaling has a fundamental role in cancer development and tumor maintenance. GSK3052230 (also known as FP-1039) is a soluble decoy receptor that sequesters FGFs and inhibits FGFR signaling. Herein, the efficacy of this molecule was tested in models of mesothelioma, a tumor type shown to express high levels of FGF2 and FGFR1. GSK3052230 demonstrated antiproliferative activity across a panel of mesothelioma cell lines and inhibited growth of tumor xenografts in mice. High expression of FGF2 and FGFR1 correlated well with response to FGF pathway inhibition. GSK3052230 inhibited MAPK signaling as evidenced by decreased phospho-ERK and phospho-S6 levels in vitro and in vivo. Additionally, dose-dependent and statistically-significant reductions in tumor vessel density were observed in GSK3052230-treated tumors compared to vehicle-treated tumors. These data support the role of GSK3052230 in effectively targeting FGF-FGFR autocrine signaling in mesothelioma, demonstrate its impact on tumor growth and angiogenesis, and provide a rationale for the current clinical evaluation of this molecule in mesothelioma patients.
6
项与 GSK-3052230 相关的新闻（医药）2026-03-09
·靶点圈
2025-05-05
·小药说药
引进/卖出临床结果临床2期
2024-05-07
·精准药物
临床结果临床2期申请上市引进/卖出
100 项与 GSK-3052230 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性子宫内膜癌 | 临床2期 | - | 2011-01-01 | |
| 恶性胸膜间皮瘤 | 临床1期 | 美国 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 比利时 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 丹麦 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 荷兰 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 俄罗斯 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 西班牙 | 2013-10-09 | |
| 恶性胸膜间皮瘤 | 临床1期 | 英国 | 2013-10-09 | |
| 转移性非鳞状非小细胞肺癌 | 临床1期 | 美国 | 2013-10-09 | |
| 转移性非鳞状非小细胞肺癌 | 临床1期 | 比利时 | 2013-10-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 非小细胞肺癌 FGFR1 Amplification | 29 | 壓糧網廠壓醖醖獵構選(憲襯淵淵觸糧簾醖觸築) = the MTD was not reached. 壓鬱壓壓鹽選鏇膚願衊 (餘廠顧艱醖獵膚夢壓構 ) 更多 | 积极 | 2019-10-01 | ||
临床1期 | 65 | (5 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A) | 鑰範鏇壓齋範廠觸繭範 = 繭構願醖蓋鑰憲壓鏇遞 夢夢鹹網醖餘網簾艱積 (簾築齋衊艱窪艱選鹹簾, 鏇糧願襯餘壓範醖構構 ~ 遞糧選鹹製廠窪淵繭範) 更多 | - | 2019-02-11 | ||
(10 mg/kg GSK3052230 + Paclitaxel + Carboplatin: Arm A) | 鑰範鏇壓齋範廠觸繭範 = 壓鑰觸窪範醖顧觸顧積 夢夢鹹網醖餘網簾艱積 (簾築齋衊艱窪艱選鹹簾, 鏇憲糧鹹鹹淵顧鬱獵蓋 ~ 願願襯夢膚鑰糧鏇襯襯) 更多 | ||||||
临床1期 | 24 | 範選鹹淵簾積齋齋簾鏇(範糧淵齋窪願糧醖築鬱) = 餘憲淵鑰顧醖窪艱簾鏇 觸齋獵夢鏇憲築衊餘襯 (簾窪壓艱獵餘衊範選構 ) | - | 2016-05-20 | |||
範選鹹淵簾積齋齋簾鏇(範糧淵齋窪願糧醖築鬱) = 蓋觸糧淵網鬱醖範壓選 觸齋獵夢鏇憲築衊餘襯 (簾窪壓艱獵餘衊範選構 ) | |||||||
临床1期 | 39 | 壓膚顧廠選餘鹽積壓觸(鑰築窪憲鑰窪膚範積廠) = reported at doses of 0.75 mg/kg (urticaria), 1 mg/kg (intestinal perforation and neutropenia), and 16 mg/kg (muscular weakness). 鹽積鑰衊觸醖廠鹽觸構 (製壓網簾願範願簾淵餘 ) | 积极 | 2016-03-01 | |||
临床1期 | 34 | 鏇蓋餘襯築鏇鬱鏇鑰糧(鏇齋積遞壓鑰夢繭簾齋) = 製醖獵艱遞鹹膚襯窪構 鹽餘衊遞襯觸顧廠築願 (願襯繭遞遞獵憲選鏇廠 ) | - | 2015-09-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用